(Q71143704)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:7358774%20AND%20SRC:MED&resulttype=core&format=json

16 October 2019

title

[Blood level and urinary excretion of activated cyclophosphamide and its deactivation products in man (author's transl)] (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:7358774%20AND%20SRC:MED&resulttype=core&format=json

16 October 2019

author name string

T Wagner

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:7358774%20AND%20SRC:MED&resulttype=core&format=json

16 October 2019

D Heydrich

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:7358774%20AND%20SRC:MED&resulttype=core&format=json

16 October 2019

G Voelcker

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:7358774%20AND%20SRC:MED&resulttype=core&format=json

16 October 2019

H J Hohorst

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:7358774%20AND%20SRC:MED&resulttype=core&format=json

16 October 2019

publication date

1 January 1980

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:7358774%20AND%20SRC:MED&resulttype=core&format=json

Journal of Cancer Research and Clinical Oncology

16 October 2019

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:7358774%20AND%20SRC:MED&resulttype=core&format=json

16 October 2019

volume

96

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:7358774%20AND%20SRC:MED&resulttype=core&format=json

16 October 2019

page(s)

79-92

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:7358774%20AND%20SRC:MED&resulttype=core&format=json

16 October 2019

issue

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:7358774%20AND%20SRC:MED&resulttype=core&format=json

https://scigraph.springernature.com/pub.10.1007/bf00412899

16 October 2019

exact match

0 references

cites work

Identification of aldophosphamide as a metabolite of cyclophosphamide in vitro and in vivo in humans

1 reference

12 December 2020

Synthesis and preliminary antitumor evaluation of 4-(SR)-sulfido-cyclophosphamides

1 reference

12 December 2020

Permeability of N,N-bis(2-chloroethyl)-diamido-phosphoric-acid into tumor cells (author's transl)

1 reference

12 December 2020

The Biotransformation of Cyclophosphamide in Man: Analysis of the Variation in Normal Subjects

1 reference

12 December 2020

Isolation and mass spectral identification of blood metabolities of cyclophosphamide: Evidence for phosphoramide mustard as the biologically active metabolite

1 reference

12 December 2020

On the binding of cyclophosphamide and cyclophosphamide-metabolites to serum-albumin (author's transl)

1 reference

12 December 2020

Permeation of cyclophosphamide (NSC-26271) metabolites into tumor cells

1 reference

12 December 2020

Mass spectrometric characterization of activated N-(2-chloroethyl)amino oxazaphosphorine derivative

1 reference

12 December 2020

Activation of cyclophosphamide in man and animals

1 reference

12 December 2020

Studies on 4-hydroperoxycyclophosphamide (NSC-181815): a simple preparation method and its application for the synthesis of a new class of "activated" sulfur-containing cyclophosphamide (NSC-26271) derivatives

1 reference

12 December 2020

The problem of oncostatic specificity of cyclophosphamide (NSC-26271): Studies on reactions that control the alkylating and cytotoxic activity

1 reference

12 December 2020

Comparative pharmacologic study in vitro and in vivo with cyclophosphamide (NSC-26271), cyclophosphamide metabolites, and plain nitrogen mustard compounds

1 reference

12 December 2020

Pharmacokinetics of cyclophosphamide in man

1 reference

12 December 2020

Techniques for the demonstration by chromatography of nitrogenous lipide constituents, sulfur-containing amino acids, and reducing sugars

1 reference

12 December 2020

Acrolein, the causative factor of urotoxic side-effects of cyclophosphamide, ifosfamide, trofosfamide and sufosfamide

1 reference

12 December 2020

Antitumor activity of cytoxan

1 reference

12 December 2020

[Studies on the spontaneous decomposition of 4-hydroxyphosphamide and 4-hydroperoxyphosphamide by means of thin-layer chromatography]

1 reference

12 December 2020

Clinical pharmacology of cyclophosphamide

1 reference

12 December 2020

Identification and pharmacokinetics of cyclophosphamide (NSC-26271) metabolites in vivo

1 reference

12 December 2020

Studies on the selective action of cyclophosphamide (NSC-26271): Inactivation of the hydroxylated metabolite by tissue-soluble enzymes

1 reference

12 December 2020

ON THE ACTIVATION OF CYCLOPHOSPHAMIDE IN VIVO AND IN VITRO

1 reference

12 December 2020

Characterization and quantitative estimation of activated cyclophosphamide in blood and urine

1 reference

12 December 2020

Identifiers

DOI

10.1007/BF00412899

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:7358774%20AND%20SRC:MED&resulttype=core&format=json

16 October 2019

1 reference